Adaptimmune Therapeutics plc
(NASDAQ: ADAP)
|
3:34 PM EDT, 04/26/24 | |||
---|---|---|---|---|
Last: $1.08 | Change: +0.02 | %Change: +2.07% | Volume: 1,098,779 |
Open: | $ 1.06 | Volume: | 1,098,779 | |
---|---|---|---|---|
High: | $ 1.09 | Yield(%) | 0.00 | |
Low: | $ 1.03 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 240.80M | |
EPS ($) | -0.52 | Shares Out: | 227.17M |
% Price Change (last 4 weeks): | -32.91 |
---|---|
% Price Change (last 13 weeks): | 43.83 |
% Price Change (last 26 weeks): | 89.29 |
% Price Change (last 52 weeks): | -22.06 |
% Price Change (year to date): | 33.67 |
Return on Equity (%): | -188.34 |
---|---|
Return on Assets (%): | -37.39 |
Return on Invested Capital (%): | -83.26 |
Gross Profit Margin (%): | 83.71 |
---|---|
Net Profit Margin (%): | -188.90 |
Operating Profit Margin (%): | -227.66 |
50-day Moving Average: | $1.38 |
---|---|
200-day Moving Average: | $0.90 |
Avg. Daily Vol. (last 50 days): | 1,613,413 |
Avg. Daily Vol. (last 200 days): | 1,016,349 |
52-wk high: | $2.05 |
52-wk low: | $0.42 |
Bid: | $1.08 |
Ask: | $1.09 |
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
|
Adaptimmune Therapeutics plc
60 Jubilee Avenue Milton Park Abingdon OX OX14 4RX Phone: 44.1235.430000 Fax: n/a http://www.adaptimmune.com |
Earnings (1year) ($): | -0.52 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 0.17 |
Cash Flow ($): | -0.46 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 2.63 |
Price/Book (x): | 4.56 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 2.85 |
---|---|
Current Ratio (x): | 2.85 |
LT Debt/Equity (x): | 50.24 |
Total Debt/Equity (x): | 63.87 |